127 related articles for article (PubMed ID: 17031113)
21. Biliopancreatic malignancy: screening the at risk patient with molecular markers.
Caldas C
Ann Oncol; 1999; 10 Suppl 4():153-6. PubMed ID: 10436811
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling.
McCarthy DM; Brat DJ; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Hum Pathol; 2001 Jun; 32(6):638-42. PubMed ID: 11431719
[TBL] [Abstract][Full Text] [Related]
23. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
24. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
26. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.
Biankin AV; Biankin SA; Kench JG; Morey AL; Lee CS; Head DR; Eckstein RP; Hugh TB; Henshall SM; Sutherland RL
Gut; 2002 Jun; 50(6):861-8. PubMed ID: 12010891
[TBL] [Abstract][Full Text] [Related]
27. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.
Heinmöller E; Dietmaier W; Zirngibl H; Heinmöller P; Scaringe W; Jauch KW; Hofstädter F; Rüschoff J
Am J Pathol; 2000 Jul; 157(1):83-92. PubMed ID: 10880379
[TBL] [Abstract][Full Text] [Related]
29. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases.
Costentin L; Pagès P; Bouisson M; Berthelémy P; Buscail L; Escourrou J; Pradayrol L; Vaysse N
Pancreatology; 2002; 2(1):17-25. PubMed ID: 12120000
[TBL] [Abstract][Full Text] [Related]
30. [Genetic profile and molecular bases of pancreatic carcinogenesis].
Sánchez-Fayos Calabuig P; Martín Relloso MJ; Porres Cubero JC
Gastroenterol Hepatol; 2007 Dec; 30(10):592-6. PubMed ID: 18028855
[TBL] [Abstract][Full Text] [Related]
31. Genetics of pancreatic cancer. From genes to families.
Hruban RH; Petersen GM; Ha PK; Kern SE
Surg Oncol Clin N Am; 1998 Jan; 7(1):1-23. PubMed ID: 9443984
[TBL] [Abstract][Full Text] [Related]
32. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.
Lüttges J; Diederichs A; Menke MA; Vogel I; Kremer B; Klöppel G
Cancer; 2000 Jun; 88(11):2495-504. PubMed ID: 10861425
[TBL] [Abstract][Full Text] [Related]
33. The genetics of pancreatic cancer.
Cowgill SM; Muscarella P
Am J Surg; 2003 Sep; 186(3):279-86. PubMed ID: 12946833
[TBL] [Abstract][Full Text] [Related]
34. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
[TBL] [Abstract][Full Text] [Related]
35. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
36. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
[TBL] [Abstract][Full Text] [Related]
37. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.
Lüttges J; Galehdari H; Bröcker V; Schwarte-Waldhoff I; Henne-Bruns D; Klöppel G; Schmiegel W; Hahn SA
Am J Pathol; 2001 May; 158(5):1677-83. PubMed ID: 11337365
[TBL] [Abstract][Full Text] [Related]
38. Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis.
Qin RY; Fang RL; Gupta MK; Liu ZR; Wang DY; Chang Q; Chen YB
World J Gastroenterol; 2004 Jan; 10(1):132-5. PubMed ID: 14695784
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic cancer: a plea for good and comprehensive morphological studies.
Algül H; Schmid RM
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):713-5. PubMed ID: 18617774
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas.
Jonson T; Albrechtsson E; Axelson J; Heidenblad M; Gorunova L; Johansson B; Höglund M
Int J Oncol; 2001 Jul; 19(1):71-81. PubMed ID: 11408925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
